In Brief: Genentech Pulmozyme
Executive Summary
Genentech Pulmozyme: Clinical supplement to modify labeling for cystic fibrosis patients with a forced vital capacity of lung less than 40% of predicted will be considered by FDA's Pulmonary-Allergy Drugs Advisory Committee at 9:30 a.m. Oct. 9 at the Holiday Inn-Gaithersburg, Md...